

NAME OF THE ISSUE: CIAN HEALTHCARE LIMITED

1	Type of issue (IPO/FPO)	Initial Public Offer (IPO) on SME Platform of BSE Limited		
2	Issue size (Rs. Lakhs)	Rs. 3791.76 Lakhs		
3	Grade of issue along with name of the rating agency	NA as the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018		
4	Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.	1.09 Times (After considering Technical rejections)		
5	QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Regulation 31 of the SEBI Listing Obligations & Disclosure Requirements), 2015)	NIL		
	i. allotment in the issue			
	ii. at the end of the 1st Quarter immediately after the listing of the issue	NIL		
	iii. at the end of 1st FY	NIL		
	iv. at the end of 2nd FY	NIL		
	v. at the end of 3rd FY	Not Applicable		
6	Financials of the issuer (as per the annual financial results submitted to stock exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015)	Rs. In Lacs		
		Parameters	1st FY	2nd FY
		Income from Operations	5704.60	7238.27
		Net Profit for the period	7.46	66.50
		Paid-up equity share capital	2336.08	2336.08
		Reserves excluding revaluation	3618.69	3651.36
7	Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)			
	i. at the end of 1st FY	Shares are frequently traded		
	ii. at the end of 2nd FY	Shares are infrequently traded		
	iii. at the end of 3rd FY	Will be updated at the end of 3rd FY		
8	Change, if any, in directors of issuer			

	from the disclosures in the offer document (See Regulation 68 and Schedule III of the SEBI (Listing Obligations & Disclosure Requirements), 2015) i. at the end of 1st FY	No change																										
	ii. at the end of 2nd FY	a) CA B. Padmanabhan- Independent Director upto 21.05.2020 b) CA Smita Khanna- Independent Director upto 02.06.2020 c) CS Mohammad Raees Sheikh- Independent Director w.e.f. 02.06.2020 d) CS Shikha Rai- Independent Director w.e.f. 28.07.2020 e) Mr. Manoj Kumar Chunilal- Non-Executive Director w.e.f. 13.11.2020 f) Mr. Paresh Arun Shah- Non-Executive Director upto 12.11.2020																										
	iii. at the end of 3rd FY	Will be updated at the end of 3rd FY																										
9	Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements), 2015) (i) as disclosed in the offer document	Not Applicable																										
	(ii) Actual implementation																											
	(iii) Reasons for delay in implementation, if any																											
10	Status of utilization of issue proceeds (as submitted to stock exchanges under (as submitted to stock exchanges under Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements), 2015) (i) as disclosed in the offer document	<table border="1"> <thead> <tr> <th>Sr. No.</th> <th>Particulars</th> <th>Amount (Rs. in Lakhs)</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Upgradation of existing plant i.e. Unit 1 situated at Roorkee, Uttarakhand India</td> <td>350.00</td> </tr> <tr> <td>2.</td> <td>Margin money for Setting up of manufacturing facility i.e. Unit 2 situated at Roorkee, Uttarakhand, India</td> <td>727.58</td> </tr> <tr> <td>3.</td> <td>Enhancement of our Company's brand through advertising and other brand-building activities</td> <td>150.00</td> </tr> <tr> <td>4.</td> <td>Long term working capital requirements</td> <td>1,000.00</td> </tr> <tr> <td>5.</td> <td>Acquisitions and other strategic initiatives</td> <td>708.73</td> </tr> <tr> <td>6.</td> <td>General Corporate Purposes</td> <td>473.77</td> </tr> <tr> <td></td> <td>Total</td> <td>3410.08</td> </tr> </tbody> </table>			Sr. No.	Particulars	Amount (Rs. in Lakhs)	1.	Upgradation of existing plant i.e. Unit 1 situated at Roorkee, Uttarakhand India	350.00	2.	Margin money for Setting up of manufacturing facility i.e. Unit 2 situated at Roorkee, Uttarakhand, India	727.58	3.	Enhancement of our Company's brand through advertising and other brand-building activities	150.00	4.	Long term working capital requirements	1,000.00	5.	Acquisitions and other strategic initiatives	708.73	6.	General Corporate Purposes	473.77		Total	3410.08
Sr. No.	Particulars	Amount (Rs. in Lakhs)																										
1.	Upgradation of existing plant i.e. Unit 1 situated at Roorkee, Uttarakhand India	350.00																										
2.	Margin money for Setting up of manufacturing facility i.e. Unit 2 situated at Roorkee, Uttarakhand, India	727.58																										
3.	Enhancement of our Company's brand through advertising and other brand-building activities	150.00																										
4.	Long term working capital requirements	1,000.00																										
5.	Acquisitions and other strategic initiatives	708.73																										
6.	General Corporate Purposes	473.77																										
	Total	3410.08																										
	(ii) Actual utilization	<table border="1"> <thead> <tr> <th>Sr. No.</th> <th>Particulars</th> <th>Amount (Rs. in Lakhs)</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Upgradation of existing plant</td> <td>350.00</td> </tr> </tbody> </table>			Sr. No.	Particulars	Amount (Rs. in Lakhs)	1.	Upgradation of existing plant	350.00																		
Sr. No.	Particulars	Amount (Rs. in Lakhs)																										
1.	Upgradation of existing plant	350.00																										

		i.e. Unit 1 situated at Roorkee, Uttarakhand India	
		2. Margin money for Setting up of manufacturing facility i.e. Unit 2 situated at Roorkee, Uttarakhand, India	727.58
		3. Enhancement of our Company's brand through advertising and other brand-building activities	150.00
		4. Long term requirements	
		5. Acquisitions initiatives	and
		6. General Corporate Purposes	473.77
		Total	3410.08
	(iii) Reasons for deviation, if any	Not Applicable	
11	Comments of monitoring agency, if applicable (See Regulation 16 of SEBI (ICDR) Regulations, 2009)	Not Applicable	
12	Price- related data Issue price (Rs):	61	

- 3 Basis for Issue Price and Comparison with Peer Group & Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated):

Accounting ratio	Name of company	<i>As disclosed in the offer document (See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Regulations, 2018)</i>	At the end of 1st FY	At the end of 2nd FY	At the end of 3rd FY
EPS	Issuer (Basic and Diluted)	2.22	0.03	0.28	Will be updated at the end of 3 rd FY
	Peer Group				
	Deccan Healthcare Limited	9.75	6.45	0.330354	
	Zota Healthcare Limited	4.23	1.12	-0.06612	
	Sakar Healthcare Limited	2.55	6.43	6.845947	
	Jenburkt Pharmaceuticals Limited	37.5	31.98	35.95781	
P/E**	Issuer (Basic and Diluted)	27.53	469.72	39.52009	
	Peer Group				
	Deccan Healthcare Limited	10.45	4.26	88.99535	
	Zota Healthcare Limited	63.12	115.9	-2094.58	
	Sakar Healthcare Limited	22.31	7.77	16.02408	
	Jenburkt Pharmaceuticals Limited	13.76	9.94	11.07965	
RoNW (%)	Issuer	22.36	0.13	1.110659	
	Peer Group				
	Deccan Healthcare Limited	34.78	13.29	0.677481	
	Zota Healthcare Limited	10.42	4.01	-0.24468	
	Sakar Healthcare Limited	8.15	11.83	10.85904	
	Jenburkt Pharmaceuticals Limited	28.1	18.59	16.75944	
NAV per share based on balance sheet	Issuer (Basic and Diluted)	10	24.49	25.63031	
	Peer Group				
	Deccan Healthcare Limited	27.02	48.51	48.76219	
	Zota Healthcare Limited	3.98	28.03	27.02412	
	Sakar Healthcare Limited	3.83	54.35	63.04373	
	Jenburkt Pharmaceuticals Limited	133.48	172.08	214.5526	

- 4 Any other material information: NA

Notes:

1. Since the equity shares of company were listed on May 23, 2019, 1st Financial year of the company will be March 31, 2020.